Navigation Links
Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma
Date:5/14/2008

DURHAM, N.C. -- By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy, according to a new study by researchers in the Duke Comprehensive Cancer Center.

We tested a compound that can weaken the tumor by targeting a protein expressed on the surface of a melanoma cell. When chemotherapy was applied to the tumor in this weakened state it was much more effective compared to conventional therapy alone, said Douglas Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs Medical Center, and senior investigator on this study. These results are extremely significant because they may help us better treat patients with this deadly condition.

Although this study was done in laboratory rats, a clinical trial applying the same concept to humans has already begun at four comprehensive cancer centers nationwide, including Duke.

The researchers published their findings from the animal study in the May 15, 2008 issue of the journal Cancer Research. Funding for this study came from the United States Department of Veterans Affairs, the Duke Institute for Genome Sciences & Policy, the Duke Comprehensive Cancer Center and Adherex Technologies, the company developing the compound that was tested in combination with chemotherapy.

After being implanted with melanoma tumors, rats were given a drug known as ADH-1, which makes it difficult for cells to bind properly to one another. The animals were then given one of two types of common chemotherapy drugs, melphalan and temozolomide.

We found that the response to ADH-1 in combination with melphalan was more dramatic than the response to the drug in combination with temozolomide," Tyler said. "The reason may be that the melphalan was infused directly into the affected area while temozolomide is given systemically.

The researchers saw a 30-fold reduction in tumor size following treatment with ADH-1 and melphalan chemotherapy compared to chemotherapy alone. Tumor size shrunk about twofold in response to ADH-1 and temozolomide, Tyler said.

We saw a complete regression of the tumors in the animal model when we used the regional melphalan chemotherapy in combination with ADH-1, which is far better than anything we have seen before with the chemotherapy alone, Tyler said. Furthermore, the addition of ADH-1 produced no additional side effects, which is an important consideration in cancer treatment.

Regional infusion of chemotherapy for melanoma is given under surgical conditions, through the artery and vein in the affected limbs. Melanoma often affects people on their extremities, with a common scenario being a mole that appears on the foot and then spreads up the leg.

These results clearly demonstrate the effectiveness of combination therapies, said Christina Augustine, Ph.D., a researcher in Dukes Department of Surgery and lead investigator on the study. Used alone the ADH-1 really didnt confer any significant benefit but in combination with the melphalan chemotherapy, we saw a powerful one-two-punch effect.

The incidence of malignant melanoma is increasing at a rate faster than any other cancer, with 60,000 new cases expected to be diagnosed this year in the United States. Melanoma that has spread beyond the primary site is rarely curable, and treatment options are limited; even when it is treated, the response rates are typically poor and most people die within six to nine months.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 22, 2017 , ... Pivot Point Consulting, a ... as the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects ... assisting clients with initial vendor selection and pre-implementation planning through go-live support and ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... Raleigh, North Carolina (PRWEB) , ... August 22, ... ... senior strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 ... elements that have become critical to his definition of “success”: physician leadership development, ...
(Date:8/21/2017)... ... 22, 2017 , ... Nanoparticle research provides an exciting path ... learning and implementing best practices for containment using ventilated safety enclosures, many of ... a better understanding of a method for safely testing nanotechnology hoods. They will ...
(Date:8/21/2017)... , ... August 21, 2017 , ... Five chefs from ... awareness for Alzheimer’s Family Center. , Guests will be able to vote for ... Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... 3, 2017  Opioid addiction and other drugs of ... costs and threatening outcomes, were problems taken on directly ... industry that support them, met this week. This according ... that drugs of abuse, procalcitonin and acute kidney injury ... organization,s 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... WASHINGTON , Aug. 2, 2017 CaryRx, a ... same day delivery service for patients in the ... the traditional retail pharmacy by providing delivery of medications through ... scheduled for future delivery or delivered within one hour to ... "We are excited to bring this invaluable service to ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation technologies, announced ... to support its strategic sales plan in Maryland ... 7D Surgical has entered into an exclusive sales representative agreement ... within those markets. ... Spartan Medical Purchases 7D Surgical ...
Breaking Medicine Technology: